We are excited to introduce you to 340B Report’s new website and email platform. It’s the culmination of many months of hard work, and we are very proud. We want to thank 340B Report’s Reshma Eggleston, Diane Slafsky and Inci
…Month: January 2021
The U.S. Health Resources and Services Administration (HRSA) Tuesday afternoon posted a new webpage describing the steps health care providers and drug manufacturers must follow to invoke the 340B program’s new administrative dispute resolution (ADR) process. It simultaneously posted 11
…
Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen
…
The incoming Democratic chairs of two key U.S. Senate committees want the federal agency in charge of the 340B program “to take immediate action to clarify that implementation of a rebate model by [drug] manufacturers would violate a material condition
…
Nevada Ryan White CARES Act grantees enrolled in 340B are strongly protesting a state AIDS Drug Assistance Program (ADAP) policy change that the clinics say will deprive them of 340B savings on drugs that pay for housing, transportation, and
…
Although groups representing 340B providers will be measured in any public statements, they are elated by the Democratic sweep of the two U.S. Senate races in Georgia on Tuesday. With Raphael Warnock (D) and Jon Ossoff’s (D) victories, Democrats have
…
UPDATE Jan. 5, 2021 2:30 p.m. EST—Shortly after we published today’s issue, Pharmaceutical Research and Manufacturers of America (PhRMA) responded to our request for comment on the U.S. Health and Human Services (HHS) General Counsel’s Dec. 30 advisory opinion on
…